Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials.

Proceedings of the National Academy of Sciences of the United States of America - 4 Sept 2018

Juraska Michal, Magaret Craig A, Shao Jason, Carpp Lindsay N, Fiore-Gartland Andrew J, Benkeser David, Girerd-Chambaz Yves, Langevin Edith, Frago Carina, Guy Bruno, Jackson Nicholas, Duong Thi Hue Kien, Simmons Cameron P, Edlefsen Paul T, Gilbert Peter B

Abstract excerpt

Two phase 3 placebo-controlled trials of the CYD-TDV vaccine, evaluated in children aged 2-14 y (CYD14) and 9-16 y (CYD15), demonstrated vaccine efficacy (VE) of 56.5% and 60.8%, respectively, against symptomatic virologically confirmed dengue (VCD). Sieve analyses were conducted to evaluate whether and how VE varied with amino acid sequence features of dengue viruses (DENVs). DENV premembrane/envelope amino acid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child, Preschool

Share to Dengue

Share to Dengue Virus

Share to Genetic Variation

Share to Genotype

Source

Open in PubMed Open full text

Identifiers

PMID: 30127007
DOI: 10.1073/pnas.1714250115
PMCID: PMC6130398

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials.PMID 30127007Read ↗

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy.Semantic proximity Read ↗

Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees.Semantic proximity Read ↗

Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection.Semantic proximity Read ↗

Exploring Dengue Infection in a Vaccinated Individual: Preliminary Molecular Diagnosis and Sequencing InsightsSemantic proximity Read ↗

Efficacy, public health impact and optimal use of the Takeda dengue vaccineSemantic proximity Read ↗

Viremia and Immunogenicity in Nonhuman Primates of a Tetravalent Yellow Fever–Dengue Chimeric Vaccine: Genetic Reconstructions, Dose Adjustment, and Antibody Responses against Wild-type Dengue Virus IsolatesSemantic proximity Read ↗

Progress of the Delta variant and erosion of vaccine effectiveness, a warning from UtahSemantic proximity Read ↗

Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization.Semantic proximity Read ↗

Preexisting Enhancing Antibodies in Vaccinated Participants Accelerate Dengue Virus 1 Infection Following Live Virus Human ChallengeSemantic proximity Read ↗

Development of New Live-Attenuated Vaccine Candidates Lacking Antibody-Dependent Enhancement (ADE) Against DengueSemantic proximity Read ↗

Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses.Semantic proximity Read ↗

Cross-serotypically conserved epitope recommendations for a universal T cell-based dengue vaccineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.